Editas Medicine Inc

NASDAQ: EDIT
$2.39
-$0.03 (-1.0%)
Real Time Data Delayed 15 Min.

EDIT Stock Chart and Intraday Price

EDIT Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 11 HURLEY ST., CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 860.02M USD
Shares Outstanding 81,674,000
Editas Medicine Inc is at the forefront of genome editing, pioneering treatments for serious diseases using CRISPR technology. With a focus on developing genomic medicines, its leading projects include EDIT-101 for a rare eye disease and reni-cel for sickle cell disease and beta-thalassemia. The company also explores cancer treatments through engineered T cells. Founded in 2013 and based in Cambridge, Massachusetts, Editas collaborates with industry leaders to advance its mission of transforming medicine.

EDIT Articles

Buy These 3 Small-Cap Stocks for 90% to 301% Returns
There has been a noticeable shift in the stock market over the last two months. Investors are moving away from former high-flying large- and mega-cap stocks into discounted small-cap names that the...
Rich Duprey
Published:

Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Trey Thoelcke
Published:

CEO Dumps 20 Million Ginkgo Bioworks Shares
Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround for the shares coming?
Trey Thoelcke
Published:

Thursday's Top Analyst Upgrades and Downgrades: Arm, CrowdStrike, Dow, Hudson Pacific Properties, Lithium Americas, LyondellBasell, Match, Pinterest, Uber and More
Thursday's top analyst upgrades and downgrades included Albemarle, Arm, CrowdStrike, Dow, Fortinet, Hudson Pacific Properties, Lithium Americas, LyondellBasell Industries, Match, Palo Alto Networks,...
Lee Jackson
Published:

Monday's Top Analyst Upgrades and Downgrades: AbbVie, Adobe, Advance Auto Parts, Anheuser-Busch, Bumble, Fortinet, Nike, Palo Alto Networks and More
Monday's top analyst upgrades and downgrades included AbbVie, Adobe, Advance Auto Parts, Anheuser-Busch InBev, Bumble, Fortinet, Nike and Palo Alto Networks.
Lee Jackson
Published:

Tuesday's Top Analyst Upgrades and Downgrades: Bill, Carnival, Oracle, Palantir, Petrobras, Valvoline, Walmart and More
Tuesday's top analyst upgrades and downgrades included Bill, Carnival, CenterPoint Energy, Editas Medicine, International Paper, Oracle, Palantir Technologies, Petrobras, SentinelOne, Trade Desk,...
Lee Jackson
Published:

Tuesday's Top Analyst Upgrades Downgrades: AMD, American Eagle Outfitters, Coinbase, Dell, Marathon Petroleum, Netflix, Spotify and More
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, American Eagle Outfitters, Azek, Bausch Health, Coinbase Global, Dell Technologies, Fidelity National Information...
Lee Jackson
Published:

Tuesday Afternoon Analyst Upgrades and Downgrades: CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and More
Tuesday afternoon's analyst upgrades and downgrades included CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and more.
Chris Lange
Published:

Friday Afternoon Analyst Upgrades and Downgrades: Barrick Gold, Newmont, Salesforce and More
Friday afternoon's analyst upgrades and downgrades included Barrick Gold, Canadian National Railway, Community Health Systems, Editas Medicine, Intellia Therapeutics, Newmont and Salesforce.com.
Chris Lange
Published:

Friday's Top Analyst Upgrades and Downgrades: American Tower, Best Buy, Beyond Meat, Freeport McMoRan, First Solar, UnitedHealth and More
Friday’s top analyst upgrades and downgrades included American Tower, Best Buy, Beyond Meat, Editas Medicine, Freeport McMoRan, First Solar and UnitedHealth.
Chris Lange
Published:

Monday Afternoon Analyst Upgrades and Downgrades: Caesars, Coinbase, Editas, Wynn and More
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Caesars Entertainment, Coinbase Global, Editas Medicine and Wynn Resorts.
Chris Lange
Published:

Thursday Afternoon Analyst Upgrades and Downgrades: Bath & Body Works, Editas, GoDaddy, PetMed, Qorvo and More
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Thursday, including Bath & Body Works, Editas Medicine, GoDaddy, PetMed Express and Qorvo.
Chris Lange
Published:

Why Cramer Thinks Companies Should Not Aspire to Meme Stock Status
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Chris Lange
Published:

Domino's, Editas, Roblox, Teva, US Steel and More Tuesday Afternoon Analyst Calls
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Domino’s Pizza, Editas Medicine, Roblox, Teva Pharmaceutical Industries and U.S. Steel.
Chris Lange
Published:

Friday's Top Analyst Upgrades and Downgrades: BP, Comcast, Coinbase, Cisco, Editas, FuelCell, Splunk, United Airlines and More
Friday’s top analyst upgrades and downgrades included BP, Comcast, Coinbase, Cisco Systems, D.R. Horton, Editas Medicine, FuelCell, KB Home, Micron Technology, Splunk, United Airlines and more.
Chris Lange
Published: